Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Belgium

Research and Innovation Action · Running

EDENT1FI European action for the Diagnosis of Early Non-clinical Type 1 diabetes For disease Interception

Coordinator
Katholieke Universiteit Leuven, Belgium
Runs
1 November 2023 to 31 October 2028
Status
Running
EU funding
€10.7m
Total cost
€22.2m
Partners
37 organisations in 14 countries
Type
Research and Innovation Action
Grant agreement
101132379

What the project is doing

In the project's own words, from its summary on CORDIS.

EDENT1FI is a unique and timely project building and operationalising an open platform for general population screening of children/adolescents for type 1 diabetes (T1D) throughout Europe. The case is compelling: T1D is a common chronic disease affecting >1 in 300 children or adolescents. Decades of European research have signposted the step-wise nature of T1D development and generated tools for early diagnosis, monitoring and disease modification.

EDENT1FI now positions Europe as the leader in early interception of T1D. Our goals are to identify individuals at earlier, pre-clinical stages, dramatically reducing clinical severity at T1D diagnosis and providing the opportunity for interventions with disease modifying therapies to delay or prevent clinical T1D. Spurred by the success of our collaborations in model European childhood screening activities and clinical networks in GPPAD and INNODIA, EDENT1FI will: establish harmonised islet autoantibody surveillance programmes to screen 200,000 children/adolescents across Europe; assess the psychosocial, medical and economic impact of screening in diverse European health systems/populations including underserved families; use state of the art metabolic sensors and biomarkers to optimise monitoring schedules for early-stage (pre-clinical) T1D aligned to maximising compliance and identifying disease progression strata; design SMART trials to expedite evaluation of disease modifying therapies; and inform and educate the public, healthcare professionals, and regulatory authorities of the new paradigms in T1D diagnosis and care.

To achieve this, EDENT1FI assembles academic, clinical and industry expertise in screening, clinical care, biomarkers, machine learning, population outreach, ethics, regulatory affairs and policy to accelerate evidence-based early T1D screening into regular healthcare in Europe. The success of these activities will promote early diagnosis and prevention pathways for other chronic childhood diseases.

Topics

Who is involved

OrganisationCityCountryRole
Katholieke Universiteit LeuvenLeuvenBelgiumCoordinator
Medizinische Universitat GrazGrazAustriaParticipant
European Diabetes ForumBrusselsBelgiumParticipant
Imcyse SALiègeBelgiumParticipant
Medtronic International Trading SARLTolochenazSwitzerlandAssociatedpartner
MiniMed International Trading SarlTolochenazSwitzerlandAssociatedpartner
Fakultni Nemocnice Motol a HomolkaPraha 5CzechiaParticipant
Hannoversche KinderheilanstaltHannoverGermanyParticipant
Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt GmbHNeuherbergGermanyParticipant
Sanofi-Aventis Deutschland GmbHFrankfurt Am MainGermanyParticipant
Technische Universitaet DresdenDresdenGermanyParticipant
Novo Nordisk A/sBagsvaerdDenmarkParticipant
Region HovedstadenHillerodDenmarkParticipant
Tampereen Korkeakoulusaatio SrTampereFinlandParticipant
Turun YliopistoTurkuFinlandParticipant
Sanofi Winthrop IndustrieGentillyFranceAssociatedpartner
Sanofi-Aventis Recherche & DeveloppementGentillyFranceAssociatedpartner
Ospedale San Raffaele SRLMilanoItalyParticipant
Universita Degli Studi Di SienaSienaItalyParticipant
Critical Path Institute StichtingAmsterdamNetherlandsAssociatedpartner
Medtronic Bakken Research Center B.v.MaastrichtNetherlandsParticipant
MiniMed Netherlands B.V.HeerlenNetherlandsParticipant
Slaski Uniwersytet Medyczny W KatowicachKatowicePolandParticipant
Warszawski Uniwersytet MedycznyWarszawaPolandParticipant
Associacao Protectora Dos Diabeticos De PortugalLisboaPortugalParticipant
Aventis Pharma Limited UKReadingUnited KingdomAssociatedpartner
Cardiff UniversityCardiffUnited KingdomAssociatedpartner
Digostics LimitedDidcotUnited KingdomAssociatedpartner
King's College LondonLondonUnited KingdomAssociatedpartner
The Chancellor, Masters and Scholars of the University of OxfordOxfordUnited KingdomAssociatedpartner
The University of BirminghamBirminghamUnited KingdomAssociatedpartner
Breakthrough T1dNew YorkUnited StatesParticipant
Diabetomics, Inc.BeavertonUnited StatesAssociatedpartner
Medtronic MiniMed, Inc.NorthridgeUnited StatesAssociatedpartner
Provention Bio IncRed BankUnited StatesAssociatedpartner
Sanofi US Services Inc.Cambridge, MassachusettsUnited StatesAssociatedpartner
The Leona M. and Harry B. Helmsley Charitable TrustNew YorkUnited StatesParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI